MDS-730: Overall Survival (OS) and Duration of Red Blood Cell-Transfusion Independence (RBC-TI) for First-Line Erythropoiesis-Stimulating Agent (ESA)-Naive Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) Treated With Luspatercept (LUSPA) vs Epoetin Alfa (EA) in the COMMANDS Trial

作者：G. Garcia-Manero, M. D. Porta, A. Zeidan, R. Komrokji, V. Pozharskaya, S. Rose, K. Keeperman, Yinzhi Lai, Sameer Kalsekar, Barkha Aggarwal, D. Miteva, D. Valcárcel, P. Fenaux, J. Shortt, U. Platzbecker, V. Santini · 发表于：Clinical Lymphoma, Myeloma & Leukemia · 年份：2025 · DOI：10.1016/s2152-2650(25)02032-4 · 被引用次数：2